Noxopharm Secures Key European Patent Allowance for Veyonda

Noxopharm Limited. ABN 50 608 966 123 Suite 3, Level 4, 828 Pacific Highway, Gordon NSW 2072 AUSTRALIA Noxopharm Limited (ASX:NOX) | ASX Announcement | 29 June 2021 Noxopharm Secures Important European Patent Allowance for Veyonda® • European Patent Office issues official Notice of Allowance on key Veyonda® patent • Key claims encompass administration of Veyonda in cancer patients receiving chemotherapy or radiotherapy • Company anticipates this allowance as boding well for other related Veyonda patent applications in Europe and other important territories such as the US. Sydney 29 June 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce that the European Patent Office (EPO) has issued a formal Notice of Allowance of claims for Patent Application No. 17778482.4, indicating an intention to move to patent grant. The important aspects of this notification are that, once granted, the patent: 1. relates to the therapeutic use of idronoxil in a suppository dosage formulation intended to provide a steady-state blood level of drug 2. will have a patent term through to April 2037. Importantly, the patent being granted only about 4 years after filing means that Noxopharm will have enforceable rights for about another 16 years 3. should cover the treatment of any cancer and is not limited to a particular cancer type 4. should cover treatment of individuals who have received or are receiving any chemotherapy, without being limited to specific chemotherapeutic drugs 5. should also cover treatment of individuals who are receiving radiotherapy, both externally or internally delivered radiotherapy. Graham Kelly, Noxopharm CEO, said, “This allowance is very pleasing validation of our strategy of building a strong IP position around Veyonda based on a series of inter-connected patents. The inter- connection is between method of administration and clinical use and removes the reliance on the strength of any single patent. A granted patent also will help underpin our commercial aim of Veyonda becoming a standard of care drug in combination with other major forms of cancer therapy.” ---------------------------------------------- Noxopharm Limited. ABN 50 608 966 123 Suite 3, Level 4, 828 Pacific Highway, Gordon NSW 2072 AUSTRALIA About Noxopharm Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome (septic shock). Veyonda® is the Company’s first pipe -line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking septic shock. Noxopharm also has drug discovery programs running in both oncology and inflammation, and is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR), active in the areas of drug development for cardiovascular and neurological diseases. To learn more, please visit: noxopharm.com END Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors. Investor, Corporate & Media enquiries: Company Secretary: Prue Kelly David Franks M: 0459 022 445 T: +61 2 8072 1400 E: [email protected] E: [email protected] Forward Looking Statements This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward- looking statement.

The release as fetched from its publisher. noxopharm.com ↗